Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) secured regulatory authorization in Spain for its Phase 2a CLEER trial of HT-001 and reported interim data showing clinical benefit in cancer patients with EGFR-inhibitor skin toxicities.
Key interim findings: primary endpoint met (rash severity ARIGA ≤1 by Week 6), >65% reported reduced pain and itching, zero patients required EGFR inhibitor dose reductions or discontinuations, and no treatment-limiting adverse events observed.
Spain authorization supports continued randomized, placebo-controlled, dose-ranging study execution and planned European expansion.
AI-generated analysis. Not financial advice.
Positive
- Spain regulatory authorization for Phase 2a CLEER trial
- Primary efficacy endpoint achieved: ARIGA ≤1 by Week 6
- >65% of patients reported meaningful reductions in pain and itching
- Zero patients required dose reduction or discontinuation of EGFR inhibitors
- No treatment-limiting adverse events observed in interim data
Negative
- None.
News Market Reaction – HOTH
On the day this news was published, HOTH gained 4.15%, reflecting a moderate positive market reaction. Argus tracked a trough of -9.8% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $541K to the company's valuation, bringing the market cap to $13.58M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before this news, HOTH was down 3.01%. Momentum peers like CRIS and PMN were moving up, while other close peers showed mixed single‑day changes, indicating stock‑specific factors rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Preclinical data update | Positive | +26.2% | HT-VA CRADA data showing liver fat metabolism reprogramming and gene changes. |
| Apr 13 | Preclinical data update | Positive | +26.2% | Positive HT-VA preclinical results vs semaglutide with metabolic gene benefits. |
| Apr 02 | Equity financing close | Negative | +3.0% | $2.0M registered direct offering closing at $0.70 per share with warrants. |
| Apr 01 | Equity financing announce | Negative | -34.9% | Announcement of $2.0M registered direct offering and concurrent private warrants. |
| Apr 01 | Clinical trial update | Positive | -34.9% | HT-001 interim success with ARIGA ≤1 by week six and Hungary expansion approval. |
News flow has been frequent and volatile, with strong gains on HT-VA data but sharp declines around financings and even positive HT-001 clinical updates, suggesting inconsistent alignment between positive R&D news and price action.
Over the last few months, Hoth has alternated between financing activity and pipeline updates. In April 2026, positive HT-VA preclinical data on liver fat metabolism and obesity coincided with gains of over 26%. Around the same time, a $2.0 million registered direct offering and a positive HT-001 interim analysis with ARIGA ≤1 by week six saw price declines of about 34.86%. Today’s HT-001 European authorization and efficacy update fits into this pattern of clinically encouraging but market-volatile milestones.
Regulatory & Risk Context
The company has an effective Form S-3 mixed shelf filed on November 14, 2025, allowing primary offerings of up to $50 million in various securities and resale of up to 1,279,587 shares. Recent 424B5 filings on April 2, 2026 and April 16, 2026 show the shelf is being actively used for capital raising.
Market Pulse Summary
This announcement combines HT-001 Phase 2a interim efficacy, including ARIGA ≤1 by week six and >65% symptom relief, with fresh regulatory authorization in Spain, advancing Hoth’s European strategy. Recent history shows the company balancing promising data with ongoing capital needs under a $50 million shelf and past offerings. Investors may watch for further regional expansions, full Phase 2a results, the Nasdaq bid-price remediation timeline, and additional financing steps as key markers.
Key Terms
phase 2a medical
randomized, placebo-controlled medical
dose-ranging medical
epidermal growth factor receptor (egfr) inhibitor medical
adverse events medical
AI-generated analysis. Not financial advice.
Regulatory Clearance in
The authorization supports the continued advancement of Hoth's randomized, placebo-controlled, dose-ranging Phase 2a study evaluating HT-001 for the treatment of dermatologic toxicities associated with epidermal growth factor receptor (EGFR) inhibitor therapies.
Interim Clinical Results Highlight Strong Efficacy Signal
Preliminary data from the ongoing study indicate:
- Patients achieved the primary efficacy endpoint, with rash severity reduced to clinically manageable levels (ARIGA ≤1) by Week 6
- Over
65% of patients reported meaningful reductions in pain and itching - Zero patients required dose reduction or discontinuation of their underlying EGFR inhibitor cancer therapy
- Favorable safety profile, with no treatment-limiting adverse events observed
These findings suggest that HT-001 may enable patients to remain on life-saving cancer therapies longer, addressing a major limitation of current oncology treatment regimens.
Regulatory Momentum + Clinical Validation
"Regulatory advancement paired with strong clinical signals has helped open up a new avenue for patients in
The
About the CLEER Trial
The CLEER Trial (Chemotherapy Longevity by Evading EGFR Inhibitor Reactions) is a Phase 2a randomized, placebo-controlled, parallel, dose-ranging study evaluating HT-001 in patients experiencing EGFR inhibitor-related dermatologic toxicities.
About HT-001
HT-001 is a novel topical therapeutic designed to target inflammatory pathways associated with cancer therapy-induced skin toxicities, with the goal of improving tolerability and enabling uninterrupted treatment.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-secures-european-authorization-in-spain-for-ht-001-phase-2a-trial-as-interim-data-show-strong-efficacy-in-cancer-patients-302762976.html
SOURCE Hoth Therapeutics, Inc.